- Home
- TPCS vs NRBO Comparison
TPCS vs NRBO Comparison
Compare TPCS & NRBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPCS
- NRBO
- Stock Information
- Founded
- TPCS 1956
- NRBO N/A
- Country
- TPCS United States
- NRBO United States
- Employees
- TPCS N/A
- NRBO N/A
- Industry
- TPCS Metal Fabrications
- NRBO Biotechnology: Pharmaceutical Preparations
- Sector
- TPCS Industrials
- NRBO Health Care
- Exchange
- TPCS Nasdaq
- NRBO Nasdaq
- Market Cap
- TPCS 32.1M
- NRBO 27.9M
- IPO Year
- TPCS N/A
- NRBO N/A
- Fundamental
- Price
- TPCS $3.14
- NRBO $2.37
- Analyst Decision
- TPCS
- NRBO Strong Buy
- Analyst Count
- TPCS 0
- NRBO 1
- Target Price
- TPCS N/A
- NRBO $10.00
- AVG Volume (30 Days)
- TPCS 22.0K
- NRBO 36.7K
- Earning Date
- TPCS 11-12-2024
- NRBO 11-07-2024
- Dividend Yield
- TPCS N/A
- NRBO N/A
- EPS Growth
- TPCS N/A
- NRBO N/A
- EPS
- TPCS N/A
- NRBO N/A
- Revenue
- TPCS $32,205,714.00
- NRBO N/A
- Revenue This Year
- TPCS N/A
- NRBO N/A
- Revenue Next Year
- TPCS N/A
- NRBO N/A
- P/E Ratio
- TPCS N/A
- NRBO N/A
- Revenue Growth
- TPCS 1.51
- NRBO N/A
- 52 Week Low
- TPCS $2.85
- NRBO $2.08
- 52 Week High
- TPCS $6.85
- NRBO $6.75
- Technical
- Relative Strength Index (RSI)
- TPCS 40.40
- NRBO 40.38
- Support Level
- TPCS $3.01
- NRBO $2.30
- Resistance Level
- TPCS $3.20
- NRBO $2.50
- Average True Range (ATR)
- TPCS 0.21
- NRBO 0.24
- MACD
- TPCS -0.04
- NRBO -0.01
- Stochastic Oscillator
- TPCS 24.68
- NRBO 23.51
About TPCS TechPrecision Corporation Common stock
Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components.
About NRBO NeuroBo Pharmaceuticals Inc.
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.